Table 1 Demographic characteristics of young patients surgically treated between January 1, 2006, and December 31, 2014 (n = 1099)
Characteristics | No. of patients (%) |
|---|---|
BC family history | |
 Yes | 113 (10.3) |
 No | 969 (88.2) |
 Unknown | 17 (1.5) |
Reproductive history* | |
 Yes | 827 (75.3) |
 No | 257 (23.4) |
 Unknown | 15 (1.4) |
Breastfeeding history | |
 Yes | 745 (67.8) |
 No | 337 (30.7) |
 Unknown | 17 (1.5) |
Tumor size | |
 T1 | 420 (38.2) |
 T2 | 508 (46.2) |
 T3 | 88 (8.0) |
 T4 | 16 (1.5) |
 Tx | 67 (6.1) |
Stage | |
 I | 282(25.7) |
 II a | 383 (34.8) |
 II b | 159 (14.5) |
 III a | 126 (11.5) |
 III b | 8 (0.7) |
 III c | 97 (8.8) |
 Unknown | 44 (4.0) |
Lymph node metastasis | |
 N0 | 585 (53.2) |
 N1 | 276(25.1) |
 N2 | 124 (11.3) |
 N3 | 94 (8.6) |
 Unknown | 20 (1.8) |
Histological grade | |
Well differentiated | 35 (3.2) |
 Moderately differentiated | 594 (54.0) |
 Poorly differentiated | 163 (14.8) |
 Unknown | 307 (27.9) |
Pathological type | |
 Invasive ductal carcinoma | 999 (90.9) |
 Invasive lobular carcinoma | 10 (0.9) |
 Others | 90 (8.2) |
Final surgery | |
 Breast-conserving surgery | 257 (23.4) |
 Mastectomy | 842 (76.6) |
Biomarker subtype | |
 HR+/HER2− | 594 (54.0) |
 HR+/HER2+ | 120 (10.9) |
 HR−/HER2+ | 75 (6.8) |
 HR−/HER2− | 201 (18.3) |
 Unknown | 109 (9.9) |
Neoadjuvant chemotherapy | |
 Yes | 176 (16.0) |
 No | 923 (84.0) |
Adjuvant chemotherapy regimens | |
 Anthracycline-based | 140 (12.7) |
 Anthracycline- and taxane-based | 884 (80.4) |
 Unknown | 67 (6.1) |
 None | 8 (0.7) |
Radiotherapy | |
 Yes | 557 (50.7) |
 No | 453 (41.2) |
 Unknown | 89 (8.1) |
Endocrine therapy | |
 Yes | 589 (53.6) |
 No | 316 (28.8) |
 Unknown | 194 (17.7) |
Ovarian function suppression | |
 Yes | 187 (17.0) |
 No | 545 (49.6) |
 Unknown | 367 (33.4) |
Trastuzumab treatment | |
 Yes | 85 (7.7) |
 No | 836 (76.1) |
 Unknown | 178 (16.2) |